Roche (RHHBY.US) CD20/CD3 bispecific antibody new indication application accepted by the FDA.

Roche (RHHBY.US) announced that the FDA has accepted the supplemental biological product license application (sBLA) for glofitamab.

Zhitong FinanceDec 5 06:16 ET

FDA Accepts Genentech's SBLA For Columvi Combination Therapy For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

BenzingaDec 5 01:11 ET

Roche (RHHBY.US) reached a nearly 0.9 billion dollar collaboration to develop therapies for autoimmune diseases.

COUR Pharmaceuticals announced a strategic collaboration and licensing agreement with Genentech, a subsidiary of Roche (RHHBY.US).

Zhitong FinanceDec 4 02:26 ET

Roche Holding AG (RHHVF) Gets a Sell From J.P. Morgan

TipRanksDec 3 02:05 ET · Ratings

Sanofi will invest approximately 1 billion euros to build a new insulin production base in peking.

Sanofi will invest approximately 1 billion euros (about 1.1 billion US dollars) to build a new insulin production facility in Peking, marking its largest single investment in china to date and part of its broader global strategy to expand production capacity in asia. The French pharmaceutical company stated on WeChat that this will be Sanofi's fourth production facility in china and its second in Peking, focusing on meeting the medication needs of local diabetes patients. Sanofi is one of the largest insulin producers globally, and the potential in the diabetes treatment market in china is immense. Sanofi noted that as of 2021, around 0.14 billion adults in mainland china suffer from diabetes.

Global Market ReportDec 2 23:21 ET

Sanofi Unveils $1 Billion China Investment to Boost Production

BNN BloombergDec 2 22:25 ET